TB Alternative Assets Ltd. Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

TB Alternative Assets Ltd. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, Holdings Channel.com reports. The fund purchased 4,360 shares of the biopharmaceutical company’s stock, valued at approximately $1,076,000. Alnylam Pharmaceuticals accounts for 0.2% of TB Alternative Assets Ltd.’s holdings, making the stock its 25th largest position.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Assenagon Asset Management S.A. grew its stake in Alnylam Pharmaceuticals by 8.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 168,320 shares of the biopharmaceutical company’s stock worth $41,531,000 after buying an additional 12,625 shares during the last quarter. Fortitude Family Office LLC increased its position in Alnylam Pharmaceuticals by 10.5% in the third quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 55 shares during the period. Sanders Morris Harris LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $777,000. First Citizens Bank & Trust Co. bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at $709,000. Finally, Krilogy Financial LLC lifted its stake in Alnylam Pharmaceuticals by 80.5% in the third quarter. Krilogy Financial LLC now owns 1,895 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 845 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ALNY shares. HC Wainwright restated a “buy” rating and set a $455.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 21st. Sanford C. Bernstein reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Bank of America cut their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Finally, Oppenheimer decreased their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $364.95.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: UBS initiated coverage of Alnylam with a Buy rating and a $354 price target, implying substantial upside from the stock’s recent level. The new coverage may be supporting investor sentiment. Alnylam third-quarter 2026 financial results webcast
• Positive Sentiment: Analysts continue to point to Alnylam’s pipeline as a potential source of longer-term growth, which could help rebuild confidence after the company’s guidance reduction. UBS’s target is also well above recent trading levels. Analysts offer insights on Alnylam
• Neutral Sentiment: Alnylam plans to webcast a conference call covering its third-quarter 2026 financial results. The upcoming update could provide clarity on product demand, guidance and the outlook for AMVUTTRA, making it a near-term catalyst for the stock. Alnylam third-quarter 2026 financial results webcast
• Negative Sentiment: Citigroup lowered its price target to $320 from $340, while Wells Fargo reduced its target to $253 from $256 and maintained an Equal Weight rating. Although Citi retained a Buy rating, the reductions reflect more cautious expectations. Alnylam analyst price target changes
• Negative Sentiment: Recent coverage highlights lingering concerns about the guidance cut and slower-than-expected AMVUTTRA demand growth. Those issues have weighed on the stock and remain a risk until Alnylam demonstrates renewed commercial momentum. Alnylam bulls and bears after guidance cut

Alnylam Pharmaceuticals Stock Up 4.3%

Shares of Alnylam Pharmaceuticals stock opened at $234.03 on Friday. The business’s fifty day moving average price is $239.10 and its two-hundred day moving average price is $274.64. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The company has a market capitalization of $31.32 billion, a P/E ratio of 43.50 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm posted ($0.51) EPS. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.68 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.